| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -177.96 M EUR | -182.73 M EUR | -145.93 M EUR | -145.06 M EUR | 287.96 M EUR | -134.83 M EUR | -98.68 M EUR | -76.04 M EUR | -64.27 M EUR | -72.19 M EUR | 7.47 M EUR | -36.85 M EUR |
| Depreciation & Amortization | 14.76 M EUR | 12.64 M EUR | 11.90 M EUR | 8.54 M EUR | 7.30 M EUR | 10.65 M EUR | 6.67 M EUR | 12.41 M EUR | 7.54 M EUR | 5.50 M EUR | 4.40 M EUR | 2.00 M EUR |
| Stock-Based Compensation | 17.68 M EUR | 22.26 M EUR | 35.09 M EUR | 34.20 M EUR | 25.64 M EUR | 21.83 M EUR | 17.53 M EUR | 10.71 M EUR | 10.28 M EUR | 6.21 M EUR | 11.62 M EUR | 8.40 M EUR |
| Capital Expenditures | 439000 EUR | 3.37 M EUR | 7.15 M EUR | 17.69 M EUR | 17.44 M EUR | 7.27 M EUR | 5.65 M EUR | 2.38 M EUR | 4.46 M EUR | 15.29 M EUR | 7.61 M EUR | 22.20 M EUR |
| Cash Flow from Investing | -321.62 M EUR | 162.97 M EUR | -205.69 M EUR | -182.73 M EUR | -67.39 M EUR | -9.48 M EUR | -6.65 M EUR | -4.25 M EUR | -5.58 M EUR | -17.17 M EUR | -8.02 M EUR | -23.94 M EUR |
| Cash Flow from Financing | 415.40 M EUR | -59.49 M EUR | 362.72 M EUR | 1.45 M EUR | 94.86 M EUR | 7.44 M EUR | 248.82 M EUR | 157.96 M EUR | 90.07 M EUR | 2.44 M EUR | 160.69 M EUR | 94.39 M EUR |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -178.40 M EUR | -186.10 M EUR | -153.08 M EUR | -162.75 M EUR | 270.52 M EUR | -142.10 M EUR | -104.33 M EUR | -78.42 M EUR | -68.73 M EUR | -87.48 M EUR | -139000 EUR | -59.05 M EUR |
uniQure N.V. is a biopharmaceutical company based in the Netherlands, specializing in the discovery, development, and commercialization of innovative gene therapies for patients with severe genetic and neurological disorders. It leverages a proprietary adeno-associated virus (AAV)-based platform to create one-time administered treatments targeting conditions such as hemophilia B, Huntington’s disease, temporal lobe epilepsy, Fabry disease, and ALS. Notable programs include AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease, supported by advanced enabling technologies like Smart AAV capsids for enhanced delivery to the central nervous system and liver, miQURE® for gene silencing, LinQURE® for multi-microRNA delivery, and GoQURE® for simultaneous gene knockdown and replacement. uniQure N.V. operates its own commercial-scale, current good manufacturing practices-compliant facilities, including one in Lexington, Massachusetts, for global production needs. Through strategic partnerships, it advances its pipeline in the biotechnology sector, focusing on biopharmaceutical applications for devastating diseases. Founded in 1998 and headquartered in Amsterdam, uniQure N.V. plays a pivotal role in transforming gene therapy innovation into potential curative options.